miRNA regulation, antitumor activity, and molecular modeling by (S)-Naproxen-1,2,4-triazole compound in human Breast cancer

Creative Commons License

ŞATIR BAŞARAN G., Sezer G., YILDIRIM M., Aktaş B., Amleh A., HAN M. İ.

Journal of Research in Pharmacy, cilt.30, sa.3, ss.812-825, 2026 (ESCI, Scopus, TRDizin) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 30 Sayı: 3
  • Basım Tarihi: 2026
  • Doi Numarası: 10.12991/jrespharm.1706713
  • Dergi Adı: Journal of Research in Pharmacy
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.812-825
  • Anahtar Kelimeler: MDA-MB-231, miR-133a-5p, molecular modeling, Naproxen, Bcl-2
  • Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
  • Erciyes Üniversitesi Adresli: Evet

Özet

This study investigated the effect of a newly synthesized original molecule with a 1,2,4-triazole with a 2-fluorophenyl ring on miRNA. (S)-Naproxen was chosen as the starting molecule for synthesis. In molecular modeling studies, compound (4a) was used to control for the Bcl-2 apoptotic marker. The primary objective was to demonstrate that the MDA-MB-231 cell line exhibited growth inhibition in a dose-dependent manner following compound treatment. The results showed that compound (4a) inhibited the motility of MDA-MB-231 cells. Compound (4a) at concentrations of 75, 150, and 300 µM significantly reduced the viability of MDA-MB-231 cells compared to the control group. IC50 value of the compound (4a) for 48 h was 57.6 µM. In our study, for the first time, miR-133a-5p was significantly up-regulated in MDA-MB-231 breast cancer cells treated with compound (4a) at different concentrations compared to the control group. As such, miR-133a-5p may play a crucial role in tumorigenesis by targeting Bcl-2 in MDA-MB-231 cells and could serve as a biomarker for therapeutic targets in breast cancer treatment.